Associated Papers
The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Shirai Y et al.
Journal of Neuro-oncology, 2024
38363490 (PubMed )
Supplement: 11060_2024_4563_MOESM1_ESM.xlsx › Supplementary_Data_2
Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.
Szpechcinski A et al.
Cancers, 2022
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
34788622 (PubMed )
Supplement: NIHMS1757901-supplement-2.xlsx › SNVs_indels
ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer.
Moreno T et al.
Oncogene, 2021
33742126 (PubMed )
Supplement: EMS118565-supplement-Suppl__Table_3.xlsx › Original_screenig
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Zeng B et al.
Frontiers in Oncology, 2021
33889545 (PubMed )
Supplement: Table_12.XLSX › Sheet1
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
30224644 (PubMed )
Supplement: NIHMS1501645-supplement-3.xlsx › Sheet1
Molecular characterization of CD44+/CD24-/Ck+/CD45- cells in benign and malignant breast lesions.
Da Cruz Paula A et al.
Virchows Archiv : an International Journal of Pathology, 2017
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L et al.
International Journal of Cancer, 2016
26340530 (PubMed )
Supplement: IJC-138-927-s005.xlsx › Tabelle1
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.
Grünewald I et al.
Oncotarget, 2015
26053092 (PubMed )
Supplement: oncotarget-06-18224-s001.pdf
Select a paper to view details